Er-Chen decoction alleviates spermatogenic dysfunction in obese mice by tuning the SIRT1/p53 axis
A traditional Chinese herbal formula reduced abnormal sperm and boosted concentration in obese mice — in mice only
Journal: Journal of Ethnopharmacology | Published: 2025-10-16 | Type: Journal Article | PMID:41109537Authors: Liu Maohui et al. — all authors from Chengdu University of Traditional Chinese Medicine or affiliated TCM institutions (Chengdu, Mianyang, Lincang)
Funding/COI: Funding not disclosed. Authors declare no competing financial interests.
Summary
A research group from Chengdu University of Traditional Chinese Medicine fed mice a high-fat diet for 8 weeks to induce obesity-related spermatogenic dysfunction, then dosed them with Er-Chen Decoction (ECD), a classic TCM herbal formula historically used for "phlegm-dampness" conditions including obesity. Medium-dose ECD reduced abnormal sperm percentage by 50% and increased sperm concentration by 60% compared to the untreated obese group. The proposed mechanism runs through SIRT1/p53 signaling: ECD appears to reverse lipid-induced SIRT1 suppression, which in turn reduces p53 acetylation and curbs mitochondria-mediated apoptosis in testicular tissue.
Claims
Medium-dose ECD reduced abnormal sperm percentage by 50% vs. HFD control (p < 0.01)
Sperm concentration increased by 60% in ECD-M group vs. HFD control (p < 0.01)
Sperm progressive motility and total motility showed "an upward trend" — not statistically significant
ECD-M upregulated tight junction proteins Occludin (p < 0.001) and β-catenin (p < 0.05), indicating partial restoration of the blood-testis barrier
Cleaved caspase-3/caspase-3 ratio decreased (p < 0.05) and Bax/Bcl-2 ratio decreased (p < 0.0001), indicating reduced apoptosis
ECD-M also reduced body weight and lipid accumulation in obese mice
Study Quality
This is an animal study — C57BL/6 mice on a high-fat diet for 8 weeks — with no human data whatsoever. The methodology is technically thorough: the authors deploy HE staining, Oil Red O staining, TEM, RT-qPCR, immunofluorescence, immunohistochemistry, Western blotting, transcriptomic analysis, and targeted mass spectrometry to characterize both the sperm outcomes and the proposed SIRT1/p53 mechanism. Network pharmacology and molecular docking were also used — these are in silico techniques that generate hypotheses but do not demonstrate biological activity on their own.
Only the medium dose (ECD-M) drove the headline results. The low- and high-dose groups either didn't reach significance or aren't prominently reported. Selectively presenting one dose tier as representative while running three is a common pattern that deserves scrutiny; the dose-response data should be examined in full.
Red Flags
No human data. Every result is from mice. Sperm parameters in a C57BL/6 obesity model do not translate directly to human male infertility.
Institutional monoculture. All authors are affiliated with TCM universities or TCM hospitals. There are no independent co-investigators outside the TCM research ecosystem.
Funding undisclosed. No funding source is listed. For TCM research published in a journal dedicated to ethnopharmacology, this is a gap — TCM formula studies are routinely funded by government agencies with explicit mandates to validate traditional medicine. Omitting this context is incomplete disclosure.
Cherry-picked dose. Low and high doses are tested, yet the summary leads entirely on medium-dose results. No clear dose-response relationship is established.
Network pharmacology overreach. Molecular docking and network pharmacology are hypothesis-generation tools presented alongside wet-lab findings as if they constitute mechanistic proof. They don't.
"Upward trend" for motility. The most clinically relevant sperm parameter — progressive motility — did not reach statistical significance. This is buried beneath the statistically significant concentration and morphology data.
Positive control is L-carnitine, a supplement with its own contested evidence base in human male infertility. The choice of comparator limits what can be inferred.
Conclusion overreaches. Calling ECD "a potential therapeutic agent for the management of obesity-related male infertility" based entirely on mouse data is the abstract working harder than the evidence warrants.
Strengths
Mechanistic depth is real: SIRT1/p53/apoptosis pathway characterized across multiple assays (WB, IHC, IF, transcriptomics) rather than just reported as an outcome
Blood-testis barrier integrity (Occludin, β-catenin) is an underexamined mediator of obesity-related spermatogenic dysfunction and is a legitimate mechanistic target
Active components of ECD were characterized by mass spectrometry, providing a chemical basis for follow-up studies
HFD obesity model is well-established and physiologically relevant to human metabolic disease
Verdict
Mechanistically interesting mouse work from an institution with an obvious stake in validating TCM. The sperm concentration and morphology numbers look compelling until you notice motility didn't reach significance, funding is absent, and every author works in TCM. The SIRT1/p53 apoptosis mechanism is plausible and the multi-assay characterization is solid for a rodent study — but the leap from "fat mice responded to an herbal decoction" to "potential therapeutic agent for human male infertility" in the conclusion is exactly the kind of overreach that makes TCM mechanistic research hard to take at face value. File this under "interesting rodent data that requires independent replication with human subjects before it means anything clinically."